US hearing set on FDA handling of Glaxo drug
By Reuters | May 21, 2007
WASHINGTON (Reuters) - A House committee will hold a hearing on June 6 on the Food and Drug Administration's oversight of the safety of GlaxoSmithKline Plc's diabetes drug, Avandia, the panel's chairman said in a statement Monday.
In a statement, Rep. Henry Waxman, a California Democrat who chairs the House Oversight and Government Reform Committee, said the hearing was called following publication of study that reported Avandia may be associated with an increase in heart attacks and deaths.
By Reuters | May 21, 2007
WASHINGTON (Reuters) - A House committee will hold a hearing on June 6 on the Food and Drug Administration's oversight of the safety of GlaxoSmithKline Plc's diabetes drug, Avandia, the panel's chairman said in a statement Monday.
In a statement, Rep. Henry Waxman, a California Democrat who chairs the House Oversight and Government Reform Committee, said the hearing was called following publication of study that reported Avandia may be associated with an increase in heart attacks and deaths.
